CClinicalTrials.gg
CompletedNCT05320341Updated Apr 11, 2022

TIVA Versus Inhalational Anesthesia and Tissue Oxygenation in Cardiac Surgery

An observational study in Cardiac Anesthesia, sponsored by Ankara City Hospital Bilkent. Completed at 1 site in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-11.

Sponsored by Ankara City Hospital Bilkent · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
104
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study was to evaluate the effect of total intravenous anesthesia (TIVA) and inhalational anesthesia techniques on tissue oxygenation in cardiac surgery. The primary objective of this study was to compare the effects of midazolam-based TIVA and sevoflurane-based (SEVO) inhalation anesthesia maintenance on intraoperative central and regional tissue oxygenation parameters.

Read the detailed description

A pressing issue in anesthesiology involves developing an understanding of the non-anesthetic effects of the medications typically used in intravenous and inhalation anesthesia methods. Few studies describe the effects of both intravenous and inhalational anesthetics on regional tissue perfusion is described under stable anesthetic conditions. There is the issue of whether inhalational anesthetics compromise regional tissue perfusion even though systemic parameters are within normal ranges. It is still debated how these effects may be different under pathophysiological conditions, such as cardiac surgery.

Maintaining tissue perfusion and oxygenation is the cornerstone of therapy for patients with cardiac disease. An imbalance in oxygen delivery and tissue oxygen consumption leads to anaerobic metabolism, cellular injury, and organ dysfunction, and is associated with poor outcomes. Consequently, monitoring tissue oxygen delivery and consumption status is of paramount importance in cardiac surgery patients. Routinely used monitors in intraoperative settings such as pulse oximetry, blood pressures, hemoglobin saturation levels, lactate, acid-base status, and central venous oxygen saturation levels all reflect tissue metabolism. Near-infrared spectroscopy (NIRS) is a non-invasive optical technique that can be used to continuously monitor tissue oxygen delivery and oxygen consumption status. Cerebral autoregulation can blunt the effect of impaired systemic oxygen delivery. Thus, cerebral NIRS may be a good predictor of neurological outcomes, but skeletal muscle NIRS serves as a follow-up indicator of many other postoperative complications due to impaired perfusion and oxygenation. Therefore, both cerebral and somatic monitoring may contribute to a more complete evaluation of hemodynamic competence. Obtaining the cerebral and somatic oxygenation levels are valuable to help in clinical management during cardiopulmonary bypass (CPB) and cardiac surgery as a whole.

The aim of this study was to evaluate the effect of total intravenous anesthesia (TIVA) and inhalational anesthesia techniques on tissue oxygenation in cardiac surgery. For this purpose, the effects of midazolam-based TIVA or sevoflurane-based inhalation anesthesia maintenance on intraoperative central and somatic tissue oxygenation parameters were compared in patients undergoing cardiac surgery.

02

Conditions studied

  • Cardiac Anesthesia

Keywords

  • tissue oxygenation
  • total intravenous anesthesia
  • inhalational anesthesia
  • cardiac surgery
  • NIRS
03

In context

Lead sponsor

Ankara City Hospital Bilkent is the lead sponsor of 424 studies on the registry; 105 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

adult patients who undergoing coronary surgeries with cardiopulmonary bypass

Inclusion criteria

  • coronary surgeries with CPB

Exclusion criteria

Exclusion Criteria:

  • emergency surgeries,
  • operations
  • ejection fraction under 40%
  • coronary surgeries in conjunction with other procedures
  • cerebrovascular accident
  • neurological disorders
  • hematologic disorder
  • chronic alcohol use
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
104 participants (actual)
Patient registry
No

Groups and cohorts

  • TIVA group

    During the anesthesia maintenance of the TIVA group, 3 μg.kg-1 fentanyl, 0.01-0.05 mg.kg-1 midazolam, and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40 and 60, approximately once every 45 minutes.

    Procedure: TIVA

  • SEVO group

    During the anesthesia maintenance of the SEVO group, 2-3% sevoflurane (1-2 MAC), 3 μg.kg-1 fentanyl and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40-60.

    Procedure: SEVO

Interventions

  • ProcedureTIVA

    During the anesthesia maintenance of the TIVA group, 3 μg.kg-1 fentanyl, 0.01-0.05 mg.kg-1 midazolam, and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40 and 60, approximately once every 45 minutes.

  • ProcedureSEVO

    During the anesthesia maintenance of the SEVO group, 2-3% sevoflurane (1-2 MAC), 3 μg.kg-1 fentanyl and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40-60.

06

What researchers measure

Primary outcomes

  1. Hemodynamic parameters

    mean arterial pressure in mmHg was recorded

    Time frame: 5 minutes after anesthesia induction

  2. Hemodynamic parameters

    heart rate (beat per minute) were recorded

    Time frame: 5 minutes after anesthesia induction

  3. Hemodynamic parameters

    mean arterial pressure (mmHg) was recorded

    Time frame: After cardiopulmonary bypass cannulation, an average of 5 minutes

  4. Hemodynamic parameters

    heart rate (beat per minute) was recorded

    Time frame: After cardiopulmonary bypass cannulation, an average of 5 minutes

  5. Hemodynamic parameters

    mean arterial pressure (mmHg) was recorded

    Time frame: 10th minute of cardiopulmonary bypass

  6. Hemodynamic parameters

    heart rate (beat per minute) was recorded

    Time frame: 10th minute of cardiopulmonary bypass

  7. Hemodynamic parameters

    mean arterial pressure (mmHg) was recorded

    Time frame: 10 minutes after cross clamp removal

  8. Hemodynamic parameters

    heart rate (beat per minute) was recorded

    Time frame: 10 minutes after cross clamp removal

  9. Hemodynamic parameters

    mean arterial pressure (mmHg) was recorded

    Time frame: 10 minutes after CPB completion

  10. Hemodynamic parameters

    heart rate (beat per minute ) was recorded

    Time frame: 10 minutes after CPB completion

  11. Hemodynamic parameters

    mean arterial pressure (mmHg) was recorded

    Time frame: upon sternum closing

  12. Hemodynamic parameters

    heart rate (beat per minute) was recorded

    Time frame: upon sternum closing

  13. Arterial gas sampling

    pH levels were recorded

    Time frame: 5 minutes after anesthesia induction

  14. Arterial gas sampling

    central venous saturation (%) levels were recorded

    Time frame: 5 minutes after anesthesia induction

  15. Arterial gas sampling

    lactate levels (mmol/L) were recorded

    Time frame: 5 minutes after anesthesia induction

  16. Arterial gas sampling

    Hemoglobin (g/dL) levels were recorded

    Time frame: 5 minutes after anesthesia induction

  17. Arterial gas sampling

    pH levels were recorded

    Time frame: After cardiopulmonary bypass cannulation, an average of 5 minutes

  18. Arterial gas sampling

    central venous saturation (%) levels were recorded

    Time frame: After cardiopulmonary bypass cannulation, an average of 5 minutes

  19. Arterial gas sampling

    lactate (mmol/L) levels were recorded

    Time frame: After cardiopulmonary bypass cannulation, an average of 5 minutes

  20. Arterial gas sampling

    hemoglobin (g/dL)levels were recorded

    Time frame: After cardiopulmonary bypass cannulation, an average of 5 minutes

  21. Arterial gas sampling

    pH levels were recorded

    Time frame: 10th minute of cardiopulmonary bypass

  22. Arterial gas sampling

    central venous saturation (%) levels were recorded

    Time frame: 10th minute of cardiopulmonary bypass

  23. Arterial gas sampling

    lactate (mmol/L) levels were recorded

    Time frame: 10th minute of cardiopulmonary bypass

  24. Arterial gas sampling

    hemoglobin (g/dL) levels were recorded

    Time frame: 10th minute of cardiopulmonary bypass

  25. Arterial gas sampling

    pH levels were recorded

    Time frame: 10 minutes after cross clamp removal

  26. Arterial gas sampling

    central venous saturation (%) levels were recorded

    Time frame: 10 minutes after cross clamp removal

  27. Arterial gas sampling

    lactate (mmol/L) levels were recorded

    Time frame: 10 minutes after cross clamp removal

  28. Arterial gas sampling

    hemoglobin (g/dL) levels were recorded

    Time frame: 10 minutes after cross clamp removal

  29. Arterial gas sampling

    pH levels were recorded

    Time frame: 10 minutes after CPB completion

  30. Arterial gas sampling

    central venous saturation (%) levels were recorded

    Time frame: 10 minutes after CPB completion

  31. Arterial gas sampling

    lactate (mmol/L) levels were recorded

    Time frame: 10 minutes after CPB completion

  32. Arterial gas sampling

    hemoglobin (g/dL) levels were recorded

    Time frame: 10 minutes after CPB completion

  33. Arterial gas sampling

    pH levels were recorded

    Time frame: upon sternum closing

  34. Arterial gas sampling

    central venous saturation (%) levels were recorded

    Time frame: upon sternum closing

  35. Arterial gas sampling

    lactate (mmol/L) levels were recorded

    Time frame: upon sternum closing

  36. Arterial gas sampling

    hemoglobin (g/dL) levels were recorded

    Time frame: upon sternum closing

  37. NIRS

    cerebral (rSO2) values were recorded

    Time frame: 5 minutes after anesthesia induction

  38. NIRS

    somatic (rSO2) values were recorded

    Time frame: 5 minutes after anesthesia induction

  39. NIRS

    cerebral (rSO2) values were recorded

    Time frame: After cardiopulmonary bypass cannulation, an average of 5 minutes

  40. NIRS

    somatic(rSO2) values were recorded

    Time frame: After cardiopulmonary bypass cannulation, an average of 5 minutes

  41. NIRS

    cerebral (rSO2) values were recorded

    Time frame: 10th minute of cardiopulmonary bypass

  42. NIRS

    somatic (rSO2) values were recorded

    Time frame: 10th minute of cardiopulmonary bypass

  43. NIRS

    cerebral (rSO2) were recorded

    Time frame: 10 minutes after cross clamp removal

  44. NIRS

    somatic (rSO2) were recorded

    Time frame: 10 minutes after cross clamp removal

  45. NIRS

    cerebral(rSO2)values were recorded

    Time frame: 10 minutes after CPB completion

  46. NIRS

    somatic (rSO2) values were recorded

    Time frame: 10 minutes after CPB completion

  47. NIRS

    cerebral(rSO2)values were recorded

    Time frame: upon sternum closing

  48. NIRS

    somatic (rSO2) values were recorded

    Time frame: upon sternum closing

07

Study locations

1 site
  • Ankara City Hospital
    Ankara, Select State/Province 06800, Turkey
08

References and documents

Publications

  • Turek Z, Sykora R, Matejovic M, Cerny V. Anesthesia and the microcirculation. Semin Cardiothorac Vasc Anesth. 2009 Dec;13(4):249-58. doi: 10.1177/1089253209353134. Epub 2009 Dec 2. PubMed 19959497 ↗
  • Bickler P, Feiner J, Rollins M, Meng L. Tissue Oximetry and Clinical Outcomes. Anesth Analg. 2017 Jan;124(1):72-82. doi: 10.1213/ANE.0000000000001348. PubMed 27308951 ↗
  • De Backer D, Dubois MJ, Schmartz D, Koch M, Ducart A, Barvais L, Vincent JL. Microcirculatory alterations in cardiac surgery: effects of cardiopulmonary bypass and anesthesia. Ann Thorac Surg. 2009 Nov;88(5):1396-403. doi: 10.1016/j.athoracsur.2009.07.002. PubMed 19853081 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05320341
Lead sponsor
Ankara City Hospital Bilkent
Responsible party
Eda Balci (Medical Doctor, Ankara City Hospital Bilkent) — Principal investigator
First posted
Apr 11, 2022
Start date
Feb 1, 2019
Primary completion
Nov 1, 2020
Completion
Mar 1, 2021
Last update
Apr 11, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion